STOCK TITAN

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
private placement

Polyrizon (NASDAQ: PLRZ) has successfully closed a $17.0 million private placement of Ordinary Shares and warrants. The offering included 35,416,667 Ordinary Units priced at $0.48 per unit, with each unit comprising one Ordinary Share or Pre-Funded Warrant and one Series A Warrant.

The Series A Warrants, exercisable for 30 months after shareholder approval, have an initial exercise price of $1.20 per Ordinary Share. Pre-Funded Warrants are priced at $0.47999 with a $0.00001 exercise price. The company plans to use the proceeds for general corporate purposes and working capital.

Aegis Capital Corp. served as the exclusive placement agent. The securities were offered privately to accredited investors and are not registered under the Securities Act. Polyrizon has agreed to file registration statements with the SEC for the resale of the shares and warrant-exercisable shares.

Polyrizon (NASDAQ: PLRZ) ha chiuso con successo un collocamento privato di azioni ordinarie e warrant per un totale di 17,0 milioni di dollari. L'offerta ha incluso 35.416.667 Unità Ordinarie, valutate a 0,48 dollari per unità, con ogni unità composta da un'azione ordinaria o un warrant pre-finanziato e un warrant di Serie A.

I warrant di Serie A, esercitabili per 30 mesi dopo l'approvazione degli azionisti, hanno un prezzo di esercizio iniziale di 1,20 dollari per azione ordinaria. I warrant pre-finanziati sono valutati a 0,47999 dollari con un prezzo di esercizio di 0,00001 dollari. L'azienda prevede di utilizzare i proventi per scopi aziendali generali e capitale circolante.

Aegis Capital Corp. ha agito come agente di collocamento esclusivo. I titoli sono stati offerti privatamente a investitori accreditati e non sono registrati ai sensi del Securities Act. Polyrizon ha concordato di presentare dichiarazioni di registrazione alla SEC per la rivendita delle azioni e delle azioni esercitabili tramite warrant.

Polyrizon (NASDAQ: PLRZ) ha cerrado con éxito una colocación privada de acciones ordinarias y warrants por un total de 17,0 millones de dólares. La oferta incluyó 35.416.667 Unidades Ordinarias a un precio de 0,48 dólares por unidad, con cada unidad compuesta por una acción ordinaria o un warrant prefinanciado y un warrant de Serie A.

Los warrants de Serie A, ejercitables durante 30 meses tras la aprobación de los accionistas, tienen un precio de ejercicio inicial de 1,20 dólares por acción ordinaria. Los warrants prefinanciados están valorados en 0,47999 dólares con un precio de ejercicio de 0,00001 dólares. La empresa planea utilizar los ingresos para fines corporativos generales y capital de trabajo.

Aegis Capital Corp. actuó como agente exclusivo de colocación. Los valores se ofrecieron de manera privada a inversores acreditados y no están registrados bajo la Ley de Valores. Polyrizon ha acordado presentar declaraciones de registro ante la SEC para la reventa de las acciones y las acciones ejercitables a través de warrants.

Polyrizon (NASDAQ: PLRZ)는 1,700만 달러 규모의 보통주 및 워런트의 사모 배정을 성공적으로 마쳤습니다. 이번 공모에는 유닛당 0.48달러에 가격이 책정된 35,416,667개의 보통 유닛이 포함되었으며, 각 유닛은 하나의 보통주 또는 사전 자금 지원 워런트와 하나의 A 시리즈 워런트로 구성됩니다.

A 시리즈 워런트는 주주 승인을 받은 후 30개월 동안 행사할 수 있으며, 보통주에 대한 초기 행사 가격은 1.20달러입니다. 사전 자금 지원 워런트의 가격은 0.47999달러이며, 행사 가격은 0.00001달러입니다. 회사는 이 자금을 일반 기업 용도 및 운영 자본으로 사용할 계획입니다.

Aegis Capital Corp.는 독점 배치 대리인으로 활동했습니다. 이 증권은 인증된 투자자에게 사적으로 제공되었으며, 증권법에 따라 등록되지 않았습니다. Polyrizon은 주식 및 워런트 행사 가능 주식의 재판매를 위해 SEC에 등록 신청서를 제출하기로 합의했습니다.

Polyrizon (NASDAQ: PLRZ) a réussi à clôturer un placement privé de 17,0 millions de dollars d'actions ordinaires et de bons de souscription. L'offre comprenait 35.416.667 unités ordinaires au prix de 0,48 dollar par unité, chaque unité étant composée d'une action ordinaire ou d'un bon de souscription préfinancé et d'un bon de souscription de série A.

Les bons de souscription de série A, exerçables pendant 30 mois après l'approbation des actionnaires, ont un prix d'exercice initial de 1,20 dollar par action ordinaire. Les bons de souscription préfinancés sont évalués à 0,47999 dollar avec un prix d'exercice de 0,00001 dollar. L'entreprise prévoit d'utiliser les produits pour des fins générales d'entreprise et de fonds de roulement.

Aegis Capital Corp. a agi en tant qu'agent de placement exclusif. Les titres ont été offerts en privé à des investisseurs accrédités et ne sont pas enregistrés en vertu de la loi sur les valeurs mobilières. Polyrizon a accepté de déposer des déclarations d'enregistrement auprès de la SEC pour la revente des actions et des actions exerçables via les bons de souscription.

Polyrizon (NASDAQ: PLRZ) hat erfolgreich eine Privatplatzierung von Stammaktien und Warrants in Höhe von 17,0 Millionen Dollar abgeschlossen. Das Angebot umfasste 35.416.667 Stamm-Einheiten, die zu einem Preis von 0,48 Dollar pro Einheit angeboten wurden, wobei jede Einheit aus einer Stammaktie oder einem vorfinanzierten Warrant und einem Serie-A-Warrant besteht.

Die Serie-A-Warrants, die 30 Monate nach der Genehmigung durch die Aktionäre ausgeübt werden können, haben einen anfänglichen Ausübungspreis von 1,20 Dollar pro Stammaktie. Vorfinanzierte Warrants sind mit 0,47999 Dollar bewertet und haben einen Ausübungspreis von 0,00001 Dollar. Das Unternehmen plant, die Einnahmen für allgemeine Unternehmenszwecke und Betriebskapital zu verwenden.

Aegis Capital Corp. fungierte als exklusiver Platzierungsagent. Die Wertpapiere wurden privat an akkreditierte Investoren angeboten und sind nicht gemäß dem Securities Act registriert. Polyrizon hat sich bereit erklärt, bei der SEC Registrierungsanträge für den Wiederverkauf der Aktien und der durch Warrants ausübbaren Aktien einzureichen.

Positive
  • Secured significant funding of $17.0 million through private placement
  • Warrants provide potential for additional future capital through exercise
Negative
  • Significant shareholder dilution through issuance of 35,416,667 new units
  • Securities offered at $0.48 per unit, indicating possible discount to market price
  • Additional dilution possible through future warrant exercises

Insights

Polyrizon's $17 million private placement represents a significant financial development for this micro-cap biotech. With a current market cap of just $2.15 million, this capital raise is approximately 8 times the company's entire market value - a substantial cash infusion that transforms their financial position.

The deal structure reveals important insights: units priced at $0.48 represent a 30% premium to the current $0.369 share price, suggesting strong investor confidence despite the company's small size. The Series A warrants with a $1.20 exercise price (more than triple the current share price) could provide additional future capital if exercised.

This financing addresses what was likely a critical capital need for Polyrizon. While dilution will occur, the premium pricing partially mitigates this concern. Without specific details on capital allocation beyond "general corporate purposes," investors should monitor how efficiently management deploys these funds to advance their intranasal hydrogel technology.

For a development-stage biotech company, securing capital at a premium significantly extends their operational runway, potentially allowing them to reach value-creating milestones without immediate financing pressure. The involvement of Aegis Capital as placement agent adds institutional credibility to the transaction.

RAANANA, ISRAEL, April 01, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced the closing of its previously announce private placement  of approximately $17.0 million of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit.

The offering consisted of the sale of 35,416,667 Ordinary Units (or Pre-Funded Units), each consisting of (i) one (1) Ordinary Share or Pre-Funded Warrant, and (ii) one (1) Series A Warrant to purchase one (1) Ordinary Share per warrant. The offering price per Ordinary Unit was $0.48 (or $0.47999 for each Pre-Funded Unit, which is equal to the offering price per Ordinary Unit sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants will be exercisable following shareholder approval and may be exercised at any time until exercised in full The initial exercise price of each Series A Warrant is $1.20 per Ordinary Share or pursuant to an alternative cashless exercise option. The Series A Warrants are exercisable following shareholder approval and will have a term of 30 months. The number of securities issuable under the Series A Warrants is subject to adjustment as described in more detail in the report on Form 6-K to be filed in connection with the offering.  

Aggregate gross proceeds to the Company were approximately $17.0 million. The transaction closed on April 1, 2025. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Aegis Capital Corp. acted as exclusive placement agent for the private placement. Greenberg Traurig, P.A. acted as counsel to the Company. Kaufman & Canoles, P.C. acted as counsel to Aegis Capital Corp.

The securities described above were sold in a private placement transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the Ordinary Shares and the Shares issuable upon exercise of the pre-funded warrants and warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Polyrizon Ltd.

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the intended use of proceeds from the offering. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com


FAQ

How much did Polyrizon (PLRZ) raise in its April 2025 private placement?

Polyrizon raised approximately $17.0 million through the private placement of Ordinary Shares and warrants at $0.48 per Ordinary Unit.

What is the exercise price of PLRZ's Series A Warrants from the April 2025 offering?

The Series A Warrants have an initial exercise price of $1.20 per Ordinary Share with a 30-month term after shareholder approval.

How many Ordinary Units did PLRZ issue in the April 2025 private placement?

Polyrizon issued 35,416,667 Ordinary Units, each consisting of one Ordinary Share or Pre-Funded Warrant and one Series A Warrant.

What will Polyrizon (PLRZ) use the $17 million private placement proceeds for?

The company plans to use the net proceeds for general corporate purposes and working capital.
Polyrizon Ltd

NASDAQ:PLRZ

PLRZ Rankings

PLRZ Latest News

PLRZ Stock Data

1.49M
2.80M
50.76%
1.9%
1.3%
Biotechnology
Healthcare
Link
Israel
Ra'anana